Public Warnings On Recalls: US FDA Clarifies Rules
Executive Summary
A new draft guidance document discusses what the agency expects to see in public warnings issued in conjunction with product recalls.
You may also be interested in...
Total Recall: FDA Final Guidance Says Firms Should Publicize Recalls Until Problem Products No Longer Used
Recall announcements should be readily accessible to the public until recalled products are gone from the market, US FDA recommends in a new corrections and removals guidance that covers all goods regulated by the agency.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.